high5immunology.tv | IBD | ECCO 2021

Spotlight Discussion – Therapy highlights & new horizons

ECCO 2021

Role of JAKi in IBD: What’s new in 2021?

A. Dignaß, S. Vermeire, F. Magro, J. Lindsay, P. Eder, P. Irving, S. Schreiber, P. Sewerin

ECCO 2021

IL23 inhibiton: Efficacy & Safety Updates

A. Dignaß, F. Magro, J. Lindsay, P. Eder, P. Sewerin

ECCO 2021

Comparing the different modes of action in IBD:…

S. Vermeire, F. Magro, A. Dignaß, S. Danese, P. Irving, S. Schreiber, P. Sewerin

ECCO 2021

Novel agents: Do we need new drugs or just…

S. Danese, S. Vermeire, S. Schreiber, A. Dignaß, F. Magro, J. Lindsay, P. Sewerin

Spotlight Discussion – Therapy concepts, diagnostics/imaging

ECCO 2021

Imaging: routine care vs. clinical trial setting? The…

A. Dignaß, D. Laharie, F. Gomollón, T. Kucharzik, P. Sewerin

ECCO 2021

Artificial Intelligence in IBD ... Even today a part of…

A. Dignaß, D. Laharie, F. Gomollón, M. Fantini, T. Kucharzik, P. Sewerin

ECCO 2021

What are the therapeutic goals in IBD? Clinical goals…

A. Dignaß, D. Laharie, F. Gomollón, M. Fantini, T. Kucharzik, P. Sewerin

ECCO 2021

Therapeutic algorithms: How to define? Transfering…

A. Dignaß, D. Laharie, F. Gomollón, M. Fantini, S. Schreiber, T. Kucharzik, P. Sewerin

Artificial Intelligence – ENG

ECCO 2021

AI: The new frontier in endoscopy interpretation

Massimo Claudio Fantini, MD, PhD

ECCO 2021

AI - Has artificial intelligence reached IBD

Axel Dignaß, MD, PhD

ECCO 2021

AI is coming!

Fernando Gomollón, MD, PhD

ECCO 2021

Classification through AI is coming!

David Laharie, MD

Artificial Intelligence – FRA/ESP/ITA/GER

ECCO 2021

Intelligenza artificiale: la nuova frontiera in…

Massimo Claudio Fantini, MD, PhD

ECCO 2021

Künstliche Intelligenz hilfreich bei Auswertung…

Axel Dignaß, MD, PhD

ECCO 2021

AI está llegando!

Fernando Gomollón, MD, PhD

ECCO 2021

L'intelligence artificielle arrive dans la RCH !

David Laharie, MD

Therapy concepts – ENG

ECCO 2021

New Therapeutic Strategies: STARDUST treat-to-target…

Axel Dignaß, MD, PhD

ECCO 2021

SEAVUE - Head-to-head comparison: Applicable for daily…

Massimo Claudio Fantini, MD, PhD

ECCO 2021

SEAVUE: Early intervention leads to great remission;…

Silvio Danese, MD, PhD

ECCO 2021

SAEVUE: The 1st biologic head-to-head trial in Crohn's…

Peter Irving, MD

ECCO 2021

SEAVUE: no difference in remission between ustekinumab…

James Lindsay, PhD

ECCO 2021

Which treatment for acute/severe UC after steroid…

David Laharie, MD

ECCO 2021

The SEAVUE Trial - will it help us to guide and…

Piotr Eder, MD, Phd

ECCO 2021

SEAVUE: From efficacy to pharmacoeconomic perspectives

Fernando Magro, MD, PhD

ECCO 2021

More JAK inhibitors - same questions!

Fernando Magro, MD, PhD

ECCO 2021

Need for early resection in Crohn's disease is not…

Piotr Eder, MD, Phd

Therapy concepts – FRA/ITA/GER/POL

ECCO 2021

Welche Therapiestrategie für welches Therapieziel?

Axel Dignaß, MD, PhD

ECCO 2021

Adalimumab vs Ustekinumab: dai risultati di confronto…

Massimo Claudio Fantini, MD, PhD

ECCO 2021

SEAVUE: Early intervention leads to great remission;…

Silvio Danese, MD, PhD

ECCO 2021

Enfin un seuil avec l'UCEIS !

David Laharie, MD

ECCO 2021

Badanie SEAVUE - czy pomoże nam pozycjonować leki…

Piotr Eder, MD, Phd

ECCO 2021

Leczenie chirurgiczne na bardzo wczesnym etapie choroby…

Piotr Eder, MD, Phd

Diagnostics and Prediction – ENG

ECCO 2021

Predictive value of Milan Ultrasound in UC

Torsten Kucharzik, MD

ECCO 2021

PREdiCCt: Predictive factors associated with fatigue in…

Torsten Kucharzik, MD

ECCO 2021

Hot topic: Intestinational ultrasound for disease…

Johan Burisch, MD

ECCO 2021

Towards UCEIS cutoff in UC

David Laharie, MD

ECCO 2021

Liquid biopsy as a novel non-invasive biomarker in IBD

Séverine Vermeire, MD

ECCO 2021

Symsptoms and signs assocation - the value of histology

Fernando Magro, MD, PhD

ECCO 2021

VARSITY: Epithelial neutrophils are very important…

Fernando Magro, MD, PhD

ECCO 2021

Liquid biopsy opens exciting window for biomarker…

Stefan Schreiber, MD

Diagnostics and Prediction – FRA/DEN/GER

ECCO 2021

Prädiktiver Wert des Darmultraschalls bei UC

Torsten Kucharzik, MD

ECCO 2021

PREdiCCt: Fatigue assoziierte prädiktive Faktoren

Torsten Kucharzik, MD

ECCO 2021

Hot topic: Tarmultralyd til monitorering af Crohn's…

Johan Burisch, MD

ECCO 2021

Quel traitement d'entretien en cas de colite aiguë…

David Laharie, MD

Therapy - new drugs – ENG

ECCO 2021

New Therapeutic Treatments in IBD: JAKi

Axel Dignaß, MD, PhD

ECCO 2021

IL-12/23 Blockade: Mechanism of action

Axel Dignaß, MD, PhD

ECCO 2021

New drugs with signifiicant efficacy: ritlecitinib,…

Silvio Danese, MD, PhD

ECCO 2021

Upadacitinib: Impressive induction data in Ulcerative…

Peter Irving, MD

ECCO 2021

Results form phase 3 induction studies with…

Severine Vermeire, MD

ECCO 2021

Upadacitinib significantly effective in UC…

James Lindsay, PhD

ECCO 2021

IL-23 inhibition with risankizumab effective for…

James Lindsay, PhD

ECCO 2021

SELECTION updates: no apparent safety concerns for…

Stefan Schreiber, MD

ECCO 2021

ADVANCE and MOTIVATE: Risankizumab with fast induction…

Stefan Schreiber, MD

ECCO 2021

VIBRATO: Ritlecitinib and brepocitinib both effective.…

Stefan Schreiber, MD

Therapy - new drugs – BEL/ITA/GER

ECCO 2021

Neue Daten zu JAK-Inhibitoren

Axel Dignaß, MD, PhD

ECCO 2021

Neue Aspekte zu IL-12 und IL-23-Antikörpern

Axel Dignaß, MD, PhD

ECCO 2021

New drugs with signifiicant efficacy: ritlecitinib,…

Silvio Danese, MD, PhD

ECCO 2021

Resultaten van de fase 3 inductie studies met…

Severine Vermeire, MD

ECCO 2021

Ritlecitinib und Brepocitinib: Neue Targets der…

Stefan Schreiber, MD

ECCO 2021

Anti-IL-23 Antikörper könnten potentielle Game-changer…

Stefan Schreiber, MD

COVID-19 – ENG

ECCO 2021

Providing CLARITY on COVID-19 in IBD

Peter Irving, MD

ECCO 2021

5-ASA - back from the other side? New COVID-19 safety…

Piotr Eder, MD, Phd

ECCO 2021

Immune response to anti-SARS-CoV-2 vaccinations in…

Piotr Eder, MD, PhD

COVID-19 - POL

ECCO 2021

5-ASA - powrót z zaświatów? Nowe dane z badania…

Piotr Eder, MD, Phd

ECCO 2021

Odpowiedź immunologiczna na szczepienia przeciw…

Piotr Eder, MD, Phd

New drugs in IBD – ENG

ECCO 2021

Wide spectrum of treatments for IBD

Fernando Gomollón, MD, PhD

New Drugs in IBD – ESP

ECCO 2021

Espectro de tratamientos amplio para IBD?

Fernando Gomollón, MD, PhD

Varia – ENG

ECCO 2021

Update ECCO-Guideline on Vaccination and Vaccination…

Torsten Kucharzik, MD

ECCO 2021

Fecal transplantation or diet for Ulcerative Colitis?

Severine Vermeire, MD

ECCO 2021

Appendectomy for Ulcerative Colitis

Johan Burisch, MD

ECCO 2021

CRAFT UC: Diet more effective than FMT? We need more…

Stefan Schreiber, MD

ECCO 2021

My perspective on ECCO2021

Fernando Gomollón, MD, PhD

ECCO 2021

Increasing prevalence of IBD in Brazil

Johan Burisch, MD

Varia – ESP/GER/DEN/BEL

ECCO 2021

Stigende forekomst af IBD i Brasilien

Johan Burisch, MD

ECCO 2021

El ECCO 2021 desde mi punto de vista

Fernando Gomollón, MD, PhD

ECCO 2021

Konditionierte Diät ist der FMT bei CU überlegen

Stefan Schreiber, MD

ECCO 2021

Neue ECCO-Leitlinie zu Infektionen und Impstrategie

Torsten Kucharzik, MD

ECCO 2021

Appendektomi ved patienter med colitis ulcerosa

Johan Burisch, MD

ECCO 2021

Stoelgangstransplantatie of dieet voor colitis ulcera?

Severine Vermeire, MD